Loading organizations...
§ Private Profile · 180 avenue du Prado, 13008 Marseille, France
Preclinical biotech company developing biologics to regenerate insulin-producing beta cells for Type 1 Diabetes treatment.
DiogenX is a preclinical-stage biotechnology company based in Marseille, France, that develops innovative recombinant protein biologics designed to regenerate insulin-producing beta cells for the treatment of Type 1 Diabetes. The organization's lead therapeutic program, DGX-01, modulates the Wnt/β-catenin signaling pathway to induce beta cell replication and is currently undergoing IND-enabling studies following successful proof-of-principle experiments in human beta cell models. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the enterprise has secured $30.3 million in total venture capital funding to advance its preclinical development pipeline. This critical financial backing comes from a syndicate of prominent corporate and institutional life sciences investors, specifically including the Boehringer Ingelheim Venture Fund, Roche Venture Fund, Omnes, and Eli Lilly and Company. DiogenX was founded in 2020 by Patrick Collombat, Jean-Pascal Tranié, and Benjamin Charles.
DiogenX has raised $42.0M across 2 funding rounds.
DiogenX has raised $42.0M in total across 2 funding rounds.
DiogenX has raised $42.0M in total across 2 funding rounds.
DiogenX's investors include Boehringer Ingelheim Venture Fund, T1D Fund, Advent France Biotechnology, Boehringer Ingelheim, Eli Lilly and Company, Omnes Capital, David Evans, Sanofi Ventures, Matthieu Coutet, Johannes Zanzinger.
DiogenX has raised $42.0M across 2 funding rounds. Most recently, it raised $37.0M Series A in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2023 | $37M Series A | — | Boehringer Ingelheim Venture Fund, T1D Fund, Advent France Biotechnology, Boehringer Ingelheim, ELI Lilly And Company, Omnes Capital, David Evans | Announced |
| Jun 1, 2020 | $5M Seed | — | Boehringer Ingelheim Venture Fund, Sanofi Ventures, T1D Fund, Matthieu Coutet, Johannes Zanzinger | Announced |
DiogenX is a preclinical-stage biotech company developing regenerative therapies for type 1 diabetes (T1D) by stimulating insulin-producing beta cell recovery in the pancreas.[1][2][4] Its lead candidate, DGX-01, is a first-in-class recombinant protein that modulates the Wnt/β-catenin signaling pathway to regenerate functional beta cells, offering a potential disease-modifying treatment beyond current insulin therapies or recent protective drugs.[1][2][5] Based in Marseille, France, with labs in Nice, the company serves T1D patients worldwide by addressing beta cell failure—the root cause of the disease—affecting millions and solving the unmet need for therapies that reverse rather than just manage symptoms.[1][3][5] Backed by $30.3M in funding from investors like Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly, and others, DiogenX shows strong growth momentum with DGX-01 advancing through IND-enabling studies as of Q3 2024.[1][3][4]
DiogenX was founded in 2020 (with some sources noting 2019) by Patrick Collombat, a leading T1D scientist whose pancreatic beta cell regeneration research forms the company's scientific foundation, alongside Jean-Pascal Tranié and Benjamin Charles, who serves as CEO.[1][2][4] Collombat's work on beta cell neogenesis provided the breakthrough idea, emerging from academic research into novel pathways for T1D treatment.[1][2] Benjamin Charles, with prior experience co-founding Imcheck Therapeutics and leading business development in biotech, healthcare consulting, and a PharmD/MBA background, drove commercialization; Tranié brings deep expertise from CEO roles at Veolia Energy and Vivendi Multimedia, plus investing in early-stage tech and biotech.[1] Early traction came from assembling a world-class diabetes expert network and securing backing from top biopharma investors, propelling DGX-01 into preclinical development.[1][2]
DiogenX rides the regenerative medicine wave in diabetes, fueled by advances in cell signaling and biologics amid a global T1D crisis affecting over 8 million people, with no curative options until recent protective therapies.[1][5] Timing is ideal post-2023 FDA approval of the first disease-modifying drug (for prevention only), highlighting demand for reversal therapies in established patients—market forces like rising diabetes prevalence (projected to hit 700M+ adults by 2045) and biopharma's $100B+ investment in novel modalities favor DiogenX.[5] It influences the ecosystem by validating academic-to-biotech translation in France's growing biotech hub (Marseille/Nice), attracting talent and capital while partnering with giants like Roche and Lilly to accelerate beta cell therapies ecosystem-wide.[1][2]
DiogenX is poised for IND filing in 2025-2026, potentially entering Phase 1 trials for DGX-01 and expanding its pipeline to type 2 diabetes or combo therapies.[1][4] Trends like AI-driven drug discovery, mRNA advancements, and personalized regen med will amplify its edge, with biopharma partnerships likely fueling a Series B or acquisition. Its influence could evolve from preclinical innovator to T1D paradigm-shifter, delivering the first scalable beta cell regenerator and transforming patient lives from daily insulin dependence to functional cures—echoing its mission to rebalance glucose homeostasis for millions.[2][5]